Supplementary Appendix from Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Supplementary Appendix: Additional methods. Carfilzomib-treated patients - Trial design; Table S1. List and classification method of the analyzed variables; Table S2. Induction treatment classification; Table S3. List of the 21 genes analyzed and mutation frequency; Table S4. Distribution of upfront treatment and ASCT in CT subgroups; Table S5. Distribution of variables in Early PD vs reference population; Figure S1. Multivariate logistic regression model evaluating risk factors associated with death within 24 months; Figure S2. Sub-analysis on patients with or without baseline del(17p) and/or TP53 mutation; Figure S3. TP53 and IGLL5 mutations at diagnosis and at first relapse in available longitudinal samples; Figure S4. Epanechnikov kernel-smoothed estimated hazard rates of progressive disease (PD) over time; Figure S5. Comparison of Seq-FISH and conventional FISH in a subgroup of patients enrolled in clinical trials and analyzed in the same centralized laboratory.